The efficacy of drug‐eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non‐small cell lung cancer
Open Access
- 18 July 2019
- journal article
- research article
- Published by Wiley in Thoracic Cancer
- Vol. 10 (9), 1770-1778
- https://doi.org/10.1111/1759-7714.13139
Abstract
Background Drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) can embolize the tumor-feeding artery and also be loaded with antitumor drugs, which can be released slowly into the local tumor environment. The effect of DEB-BACE in patients with lung cancer remains unclear. We evaluated the efficacy and safety of DEB-BACE with gemcitabine-loaded CalliSpheres (R) beads in patients with non-small cell lung cancer (NSCLC). Methods From May 2017 to December 2018, six patients with NSCLC who were ineligible or refused to receive standard treatment underwent DEB-BACE with gemcitabine-loaded CalliSpheres (R) beads. The primary endpoint was the objective response rate (ORR). The secondary endpoints were progression-free survival (PFS), overall survival (OS), and quality of life. Safety was evaluated by the occurrences of adverse events and serious adverse events. Results All patients were treated with DEB-BACE loaded with gemcitabine (800 mg) using CalliSpheres (R) beads. Five patients also received transarterial infusion with nedaplatin (80-100 mg). Of the six patients, five underwent a second session of DEB-BACE, with intervals of one month between the first and second session. The median follow-up time was 16.5 months (7.0-23.0 months). ORR and disease control rate were 50.0% and 100.0%, 50.0% and 83.3%, 50.0% and 66.7% respectively at 2, 4, and 6 months after DEB-BACE. One patient maintained a partial response and the other five had progressive disease, of whom two patients died and the other three remained alive receiving targeted therapy, radiotherapy, transarterial infusion or thermal ablation. The median PFS was 8.0 months (4-23 months), and the 6- and 12 month PFS rates were 66.7% and 16.7%, respectively. The median OS was 16.5 months (7-23 months), and the six and 12 month OS rates were 100.0% and 66.7%, respectively. Hemoptysis, cough and dyspnea disappeared after DEB-BACE in four patients. Global quality of life, physical and emotional functioning were all significantly improved at two months (P < 0.05). There were no serious adverse events. Conclusions DEB-BACE with gemcitabine-loaded CalliSpheres beads is a feasible and well-tolerated treatment for patients with NSCLC who are ineligible or refuse to receive standard treatment.Keywords
Funding Information
- National Key Research and Development Program of China (2016YFC0902003)
This publication has 27 references indexed in Scilit:
- [Efficacy for artery chemoembolization combined with radiofrequency ablation in the treatment of advanced non-small cell lung cancer].Published by Ovid Technologies (Wolters Kluwer Health) ,2016
- [Transcatheter Arterial Chemoembolization with Super absorbent Polymer Microspheres for a Large Lung Cystic Adenocarcinoma in the Left Pulmonary Cavity].2015
- [Trans-Arterial Chemoembolization Therapy for Refractory Advanced Non-Small Cell Lung Cancer with Spherical Embolic Material--A Single Case Report].2015
- Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts OpinionCardioVascular and Interventional Radiology, 2015
- Comparison of Drug Release and Pharmacokinetics after Transarterial Chemoembolization Using Diverse Lipiodol Emulsions and Drug-Eluting BeadsPLOS ONE, 2014
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Autism Associated Gene, ENGRAILED2, and Flanking Gene Levels Are Altered in Post-Mortem CerebellumPLOS ONE, 2014
- Transcatheter Arterial Embolization With Spherical Embolic Agent for Pulmonary Metastases From Renal Cell CarcinomaCardioVascular and Interventional Radiology, 2013
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010